View in EDS HTML Full Text PDF Full Text

BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides.

Saved in:
Bibliographic Details
Title: BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides.
Authors: Sakamoto K; Souseikai Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, Japan., Matsuki S; Souseikai Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, Japan., Matsuguma K; Souseikai Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, Japan., Yoshihara T; Souseikai Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, Japan., Uchida N; Clinical Pharmacology, Pharmacology, Showa University School of Medicine, Tokyo, Japan., Azuma F; Research & Development, AstraZeneca KK, Osaka, Japan., Russell M; AstraZeneca, Protein Biomarkers, Personalised Healthcare and Biomarkers, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Alderley Park, UK., Hughes G; AstraZeneca, Protein Biomarkers, Personalised Healthcare and Biomarkers, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Alderley Park, UK., Haeberlein SB; Neuroscience, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Waltham, MA, USA., Alexander RC; Neuroscience, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Waltham, MA, USA., Eketjäll S; Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Huddinge, Sweden., Kugler AR; Neuroscience, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Waltham, MA, USA.
Source: Journal of clinical pharmacology [J Clin Pharmacol] 2017 Nov; Vol. 57 (11), pp. 1460-1471. Date of Electronic Publication: 2017 Jun 15.
Publication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial
Journal Info: Publisher: Wiley Country of Publication: England NLM ID: 0366372 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-4604 (Electronic) Linking ISSN: 00912700 NLM ISO Abbreviation: J Clin Pharmacol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 28618005
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Sakamoto+K%22">Sakamoto K</searchLink>; Souseikai Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, Japan.<br /><searchLink fieldCode="AU" term="%22Matsuki+S%22">Matsuki S</searchLink>; Souseikai Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, Japan.<br /><searchLink fieldCode="AU" term="%22Matsuguma+K%22">Matsuguma K</searchLink>; Souseikai Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, Japan.<br /><searchLink fieldCode="AU" term="%22Yoshihara+T%22">Yoshihara T</searchLink>; Souseikai Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, Japan.<br /><searchLink fieldCode="AU" term="%22Uchida+N%22">Uchida N</searchLink>; Clinical Pharmacology, Pharmacology, Showa University School of Medicine, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Azuma+F%22">Azuma F</searchLink>; Research & Development, AstraZeneca KK, Osaka, Japan.<br /><searchLink fieldCode="AU" term="%22Russell+M%22">Russell M</searchLink>; AstraZeneca, Protein Biomarkers, Personalised Healthcare and Biomarkers, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Alderley Park, UK.<br /><searchLink fieldCode="AU" term="%22Hughes+G%22">Hughes G</searchLink>; AstraZeneca, Protein Biomarkers, Personalised Healthcare and Biomarkers, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Alderley Park, UK.<br /><searchLink fieldCode="AU" term="%22Haeberlein+SB%22">Haeberlein SB</searchLink>; Neuroscience, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Alexander+RC%22">Alexander RC</searchLink>; Neuroscience, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Eketjäll+S%22">Eketjäll S</searchLink>; Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Huddinge, Sweden.<br /><searchLink fieldCode="AU" term="%22Kugler+AR%22">Kugler AR</searchLink>; Neuroscience, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Waltham, MA, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220366372%22">Journal of clinical pharmacology</searchLink> [J Clin Pharmacol] 2017 Nov; Vol. 57 (11), pp. 1460-1471. <i>Date of Electronic Publication: </i>2017 Jun 15.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley%22">Wiley </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>0366372 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1552-4604 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200912700%22">00912700 </searchLink><i>NLM ISO Abbreviation: </i>J Clin Pharmacol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=28618005
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/jcph.950
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1460
    Titles:
      – TitleFull: BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Sakamoto K
      – PersonEntity:
          Name:
            NameFull: Matsuki S
      – PersonEntity:
          Name:
            NameFull: Matsuguma K
      – PersonEntity:
          Name:
            NameFull: Yoshihara T
      – PersonEntity:
          Name:
            NameFull: Uchida N
      – PersonEntity:
          Name:
            NameFull: Azuma F
      – PersonEntity:
          Name:
            NameFull: Russell M
      – PersonEntity:
          Name:
            NameFull: Hughes G
      – PersonEntity:
          Name:
            NameFull: Haeberlein SB
      – PersonEntity:
          Name:
            NameFull: Alexander RC
      – PersonEntity:
          Name:
            NameFull: Eketjäll S
      – PersonEntity:
          Name:
            NameFull: Kugler AR
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: 2017 Nov
              Type: published
              Y: 2017
          Identifiers:
            – Type: issn-electronic
              Value: 1552-4604
          Numbering:
            – Type: volume
              Value: 57
            – Type: issue
              Value: 11
          Titles:
            – TitleFull: Journal of clinical pharmacology
              Type: main
ResultId 1